Pelthos Therapeutics Inc.
PTHS- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001919246
In the last 90 days, Pelthos Therapeutics Inc. insiders filed 0 open-market purchases and 3 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $37.4M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Pelthos Therapeutics Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 14 | 15 | +1 |
| Shares | 462.8K | 899.4K | +436.6K (+94.3%) |
| Value | $13.0M | $27.9M | +$14.9M (+115.2%) |
New holders (4)
Institutions that held Pelthos Therapeutics Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| J. Goldman & Co LP | 78,006 | $2.42M | 0.09% |
| Cantor Fitzgerald, L. P. | 34,990 | $1.08M | 0.03% |
| Millennium Management LLC | 11,057 | $342.8K | 0.00% |
| Pale Fire Capital SE | 8,100 | $251.1K | 0.03% |
Sold out (3)
Institutions that held Pelthos Therapeutics Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Tower Research Capital LLC (TRC) | 827 | $23.2K |
| JPMorgan Chase & Co | 1 | $28 |
| Citigroup Inc | 1 | $28 |